NCT06122402

Brief Summary

Skin injury due to the use of medical adhesives is a common but under recognized complication in children. To prevent central venous catheter-related complications, care interventions should be planned in such a way that they do not lead to medical adhesive-related skin injury. Systematic administration of preventive care interventions is needed to reduce skin injuries associated with medical adhesive used for central venous catheter fixation. The SECURE Care Bundle has been developed by researchers based on the latest evidence to prevent medical adhesive-related skin injuries associated with central venous catheter fixation in children.The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, correctly applying and removing medical adhesives and registering medical adhesive related skin injury. This study aims to evaluate the effectiveness of the SECURE Care Bundle in reducing MARSI incidence related to CVC fixation in pediatric patients and to examine its influence on the MARSI occurrence time. Hypotheses Null Hypothesis (H₀): There is no effect of the SECURE Care Bundle in preventing skin injuries related to central venous catheter (CVC) fixation in children. Hypothesis 1 (H₁): Children who receive the SECURE Care Bundle experience a lower incidence of medical adhesive-related skin injury due to CVC fixation compared to those who receive standard care. Hypothesis 2 (H₂): Children who receive the SECURE Care Bundle develop medical adhesive-related skin injury due to CVC fixation later than those who receive standard care. This quasi-experimental study follows a pre-test/post-test control group design and will be conducted in the Pediatric Cardiovascular Intensive Care Unit. A total of 92 pediatric patients will participate. Following informed consent, patients will be allocated into intervention (n=46) and control (n=46) groups. Data collection tools will include a descriptive information form, the Braden QD Scale, a skin observation form, and the SECURE Care Bundle checklist. The intervention group will receive the SECURE Care Bundle, and its effectiveness will be assessed by analyzing MARSI incidence and time to onset.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
91

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 5, 2023

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 8, 2023

Completed
8 months until next milestone

Study Start

First participant enrolled

July 1, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
Last Updated

November 25, 2025

Status Verified

November 1, 2025

Enrollment Period

10 months

First QC Date

November 5, 2023

Last Update Submit

November 20, 2025

Conditions

Keywords

childrenmarsimedical adhesive-related skin injurycare bundleskin injury

Outcome Measures

Primary Outcomes (1)

  • Incidence of medical adhesive-related skin injury due to central venous catheter fixation

    Incidence of medical adhesive-related skin injury due to central venous catheter fixation refers to the proportion of patients who develop medical adhesive-related skin injury (MARSI). This outcome will be assessed in both the pre-test and post-test groups, and the results will be compared to evaluate the effectiveness of the intervention.Three types of MARSI incidence rates will be calculated: (1)the rate per 100 patients, (2)the rate per 100 MAs, and (3)the rate per 1000 days of MA use. The formulas for calculating each incidence rate will be as follows: (1)incidence rate per 100 patients= number of MARSIs/number of patients × 100, (2)incidence rate per 100 MAs= number of MARSIs/number of MAs × 100, and (3)incidence rate per 1000 days of MA use= number of MARSIs/number of days of MA usage × 1000.

    From Day 1 (postoperative admission to PCCU) to MARSI occurrence or discharge, up to 30 days

Secondary Outcomes (1)

  • MARSI occurrence time

    From Day 1 (the day of CVC insertion and fixation) to the first occurrence of MARSI or end of treatment, up to 30 days

Study Arms (2)

SECURE Care Bundle

EXPERIMENTAL

The SECURE Care Bundle has been developed by researchers based on the latest evidence to prevent medical adhesive-related skin injuries associated with central venous catheter fixation in children. The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, correctly applying and removing medical adhesives and registering medical adhesive related skin injury.

Other: SECURE Care Bundle

Standart Care

ACTIVE COMPARATOR

No intervention will be applied to this group. No intervention will be applied to this group. The care provided in the clinic will continue to be provided in the same way.

Procedure: Standart Care

Interventions

The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives including CHG dressing and silicone based remover.

SECURE Care Bundle
Standart CarePROCEDURE

It is applied in routine care in the clinic. There is no standardization and no procedure for checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives. Only CHG dressing is used for central venous catheter care.

Standart Care

Eligibility Criteria

AgeUp to 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Patients aged 0 to 18 years.
  • Underwent cardiovascular surgery and had a jugular central venous catheter (CVC) inserted.
  • Admitted to the Pediatric Cardiovascular Intensive Care Unit (PCCU) in the postoperative period.
  • Have a Braden QD Scale score of 12 or higher at admission.
  • Parental informed consent obtained via a voluntary participation form.

You may not qualify if:

  • Patients who had a central venous catheter inserted in another unit prior to cardiovascular surgery.
  • Patients with pre-existing skin injury around the catheter site before insertion.
  • Patients with a known history of dermatological disease.
  • Patients with a known allergy to any of the products used in the study.
  • Patients for whom catheter leakage occurs.
  • Patients whose catheter is removed due to complications (e.g., infection, dislodgement, or other clinical reasons).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Istanbul University- Cerrahpaşa

Istanbul, Şisli, 34116, Turkey (Türkiye)

Location

Istanbul University- Cerrahpaşa

Istanbul, Şişli, 34381, Turkey (Türkiye)

Location

Related Publications (1)

  • Sensoy O, Caglar S. SECURE Care Bundle to Prevent Medical Adhesive-Related Skin Injury in Paediatric Central Venous Catheter Fixation: A Study Protocol. Nurs Crit Care. 2025 Nov;30(6):e70226. doi: 10.1111/nicc.70226.

Study Officials

  • Özlem Şensoy

    İstanbul University-Cerrahpaşa

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: The study is designed as a quasi-experimental study with a pre-test and post-test control group design.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 5, 2023

First Posted

November 8, 2023

Study Start

July 1, 2024

Primary Completion

April 30, 2025

Study Completion

April 30, 2025

Last Updated

November 25, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will share

Study Protocol and Statistical Analysis Plan will be provided.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
The data will be become available upon request for three years.
Access Criteria
The data will become available upon request by contacting with principle investigator.

Locations